Robert W. Baird Forecasts Strong Price Appreciation for Caris Life Sciences (NASDAQ:CAI) Stock

Caris Life Sciences (NASDAQ:CAI) had its price target raised by investment analysts at Robert W. Baird from $26.00 to $28.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s price objective indicates a potential upside of 39.03% from the stock’s previous close.

Several other research analysts have also recently weighed in on CAI. Wall Street Zen cut shares of Caris Life Sciences from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Weiss Ratings restated a “sell (d)” rating on shares of Caris Life Sciences in a research report on Monday, December 29th. Canaccord Genuity Group lifted their price objective on shares of Caris Life Sciences from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Monday, December 22nd. Finally, Evercore set a $38.00 target price on Caris Life Sciences in a research note on Monday, January 5th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $33.50.

Caris Life Sciences Stock Performance

NASDAQ:CAI opened at $20.14 on Friday. Caris Life Sciences has a 52-week low of $17.15 and a 52-week high of $42.50. The company’s fifty day simple moving average is $24.42. The company has a quick ratio of 9.36, a current ratio of 9.93 and a debt-to-equity ratio of 0.79. The company has a market capitalization of $5.68 billion and a price-to-earnings ratio of -43.78.

Caris Life Sciences (NASDAQ:CAI) last announced its earnings results on Thursday, February 26th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.27. The business had revenue of $292.89 million during the quarter, compared to the consensus estimate of $281.00 million. Caris Life Sciences’s revenue was up 125.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.73) earnings per share.

Insiders Place Their Bets

In related news, insider Luke Thomas Power sold 62,250 shares of the stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the completion of the sale, the insider directly owned 99,571 shares in the company, valued at $2,646,597.18. This represents a 38.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 7.80% of the stock is owned by corporate insiders.

Institutional Trading of Caris Life Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Global Retirement Partners LLC grew its holdings in shares of Caris Life Sciences by 99,900.0% in the fourth quarter. Global Retirement Partners LLC now owns 1,000 shares of the company’s stock worth $27,000 after purchasing an additional 999 shares during the last quarter. Olistico Wealth LLC purchased a new stake in Caris Life Sciences during the 4th quarter valued at $31,000. MetLife Investment Management LLC grew its holdings in Caris Life Sciences by 84.0% in the 4th quarter. MetLife Investment Management LLC now owns 1,654 shares of the company’s stock worth $45,000 after acquiring an additional 755 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new position in shares of Caris Life Sciences in the fourth quarter valued at about $67,000. Finally, Federated Hermes Inc. bought a new position in shares of Caris Life Sciences during the fourth quarter valued at about $81,000.

Key Stories Impacting Caris Life Sciences

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Q4 beat and strong revenue growth — CAI reported GAAP EPS of $0.28 (well above estimates) and Q4 revenue of ~$293M, up ~125% YoY, demonstrating accelerating top‑line momentum. Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
• Positive Sentiment: Major interim Achieve 1 readout — The company announced interim data showing Caris Detect (WGS + AI) had superior sensitivity and specificity vs. methylation‑based approaches, a milestone for its MCED launch and long‑term growth potential in early cancer detection. Caris Life Sciences Completes Interim Readout of Achieve 1 Study
• Positive Sentiment: 2026 revenue guidance reaffirmed/raised — Management guided full‑year 2026 revenue to roughly $1.0B–$1.02B (above consensus), supporting sustained growth expectations as profiling services and new product launches scale. Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
• Positive Sentiment: Analyst support — Robert W. Baird initiated coverage / raised its price target (to $28 with an Outperform stance), bringing new institutional attention that can boost demand for the stock. Baird Initiates Coverage of Caris Life Sciences, Inc. (CAI) with an Outperform Rating
• Positive Sentiment: Product enhancement — Caris added an AI‑powered breast cancer signature to its Caris Molecular Tumor Board Report, expanding clinical utility and potential revenue per case in precision oncology. Caris Life Sciences (CAI) Adds New AI-powered Breast Cancer Signature to its Report
• Neutral Sentiment: Mixed analyst moves — BTIG lowered its price target from $45 to $38 but maintained a Buy rating; still bullish but the cut tempers some upside expectations. BTIG price target note
• Neutral Sentiment: Further reading / call details — The Q4 earnings call transcript and additional materials are available for investors who want management commentary on Caris Detect commercialization timing and margin cadence. Caris Life Sciences, Inc. (CAI) Q4 2025 Earnings Call Transcript

Caris Life Sciences Company Profile

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.